Ixazomib-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial

Detalles Bibliográficos
Autores principales: Zweegman, Sonja, Stege, Claudia A.M., Haukas, Einar, Schjesvold, Fredrik H., Levin, Mark-David, Waage, Anders, Leys, Rineke B.L., Klein, Saskia K., Szatkowski, Damian, Axelsson, Per, Do, Trung Hieu, Knut-Bojanowska, Dorota, van der Spek, Ellen, Svirskaite, Asta, Klostergaard, Anja, Salomo, Morten, Blimark, Celine, Ypma, Paula F., Mellqvist, Ulf-Hendrik, Poddighe, Pino J., Stevens-Kroef, Marian, van de Donk, Niels W.C.J., Sonneveld, Pieter, Hansson, Markus, van der Holt, Bronno, Abildgaard, Niels
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2020
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7716358/
https://www.ncbi.nlm.nih.gov/pubmed/33256392
http://dx.doi.org/10.3324/haematol.2019.240374

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7716358/
https://www.ncbi.nlm.nih.gov/pubmed/33256392
http://dx.doi.org/10.3324/haematol.2019.240374

Ejemplares similares